24 results
Thumbnail

D2.65 - Clinical relevance of sensitizations to pneumoallergens detected in southern Spain

Thumbnail

D2.66 - Deciphering The Molecular Profiles Between Asthma and Urticaria Using Transcriptomic Profiling

Thumbnail

D2.67 - Relation betwween IL-6 and asthma in children and adolescent

Thumbnail

D2.69 - Symptom Variability in Hypereosinophilic Syndrome: Observations From a Large Cohort Study

Thumbnail

D2.70 - The Impact of Comorbidity of respiratory and atopic diseases on Mental Health and Wellbeing: a Community Survey in the US and Eastern Europe

Thumbnail

D2.71 - Comprehensive approach to severe bronchial asthma: a case study and the role of biologic therapy

Thumbnail

D2.72 - Analysis of asthma prevalence and risk factors in infantile atopic dermatitis using data from the Korean national health insurance serice

Thumbnail

D2.73 - Activation-induced marker (AIM) assay to study allergic skin reactions: a case study on p-phenylenediamine

Thumbnail

D2.74 - Analytical Verification of House Dust Mite Allergen Assays on the IMMULITE 2000 XPi System*

Thumbnail

D2.75 - Allergy to insects in children

Thumbnail

D2.76 - When Eosinophilia Persists: Unmasking an Unexpected Diagnosis in a Dupilumab Treated Atopic Dermatitis Patient

Thumbnail

D2.77 - A Novel Neural Network for Quantifying Wheal and Erythema in Skin Prick Testing

Thumbnail

D2.78 - Hypersensitivity Reactions to Biologics in Patients with Th1- and Th17-Driven Immune-Mediated Diseases: A Series of Three Cases

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series